New post-hoc analyses highlighting the clinical benefit of evenamide for patients with treatment-resistant schizophrenia (TRS) or those inadequately responding to their
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 16, 2025, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a
The importance of glutamate release modulation by evenamide used as an add-on therapy for patients with schizophrenia inadequately responding to their second-
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study
Ad hoc announcement pursuant to Art. 53 LR
New findings published in Neuropsychopharmacology are the first to demonstrate that evenamide targets the key site of schizophrenia
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 23, 2025, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its
Milan, Italy and Morristown, NJ, USA – March 11, 2025 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
